FDA reverses course and will review Moderna’s mRNA-based flu vaccine
US drug regulator originally refused to consider application, fueling critics’ concern about alleged ‘anti-vaccine agenda’ The Food and Drug Administration (FDA) reversed course on Wednesday and will now review Moderna’s application for the first mRNA-based flu vaccine after initially declining to consider it. Moderna announced that the US drug regulator will move forward with reviewing … Read more